Atlas Venture led the series A round.
Quartet Medicine, a biotech spin-out of École Polytechnique Fédérale de Lausanne’s (EPFL) and Boston Children’s Hospital, has secured $17m in its series A funding round. Atlas Venture led the round.
Atlas Venture had supported the original tech transfer process of the biotech, which is working on a range of therapeutics for chronic pain and inflammation.
Novartis Venture Funds, Pfizer Venture Investments and Partners Innovation Fund also participated. As part of the investment, Henry Skinner of Novartis Venture Funds will join Quartet’s board.
Quartet will use the investment to advance development of its lead candidate. It is based on original research by co-founders Kevin Pojasek, entrepreneur-in-residence at Atlas, and Dr Clifford Woolf, Boston Children’s Hospital and Harvard Medical School, and Kai Johnsson, EPFL.
Bruce Booth, chairman at Quartet and partner at Atlas, said: “Atlas Venture is proud to be leading this strong syndicate of investors after providing seed capital to support the formation of Quartet and to achieve early target validation. We are capitalising on recent advances in human genetics that are revealing new mechanisms and, ultimately, novel targets for drug discovery and development in the challenging and underserved therapeutic area of chronic pain.”
